Tanimura, K.; Takeda, T.; Yoshimura, A.; Honda, R.; Goda, S.; Shiotsu, S.; Fukui, M.; Chihara, Y.; Uryu, K.; Takei, S.;
et al. Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study. Cancers 2023, 15, 4358.
https://doi.org/10.3390/cancers15174358
AMA Style
Tanimura K, Takeda T, Yoshimura A, Honda R, Goda S, Shiotsu S, Fukui M, Chihara Y, Uryu K, Takei S,
et al. Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study. Cancers. 2023; 15(17):4358.
https://doi.org/10.3390/cancers15174358
Chicago/Turabian Style
Tanimura, Keiko, Takayuki Takeda, Akihiro Yoshimura, Ryoichi Honda, Shiho Goda, Shinsuke Shiotsu, Mototaka Fukui, Yusuke Chihara, Kiyoaki Uryu, Shota Takei,
and et al. 2023. "Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study" Cancers 15, no. 17: 4358.
https://doi.org/10.3390/cancers15174358
APA Style
Tanimura, K., Takeda, T., Yoshimura, A., Honda, R., Goda, S., Shiotsu, S., Fukui, M., Chihara, Y., Uryu, K., Takei, S., Katayama, Y., Hibino, M., Yamada, T., & Takayama, K.
(2023). Predictive Value of Modified Glasgow Prognostic Score and Persistent Inflammation among Patients with Non-Small Cell Lung Cancer Treated with Durvalumab Consolidation after Chemoradiotherapy: A Multicenter Retrospective Study. Cancers, 15(17), 4358.
https://doi.org/10.3390/cancers15174358